Hepatic failure and hepatorenal syndrome secondary to erlotinib: a possible etiology of complications in a patient with pancreatic cancer.
Gunturu
Krishna S
KS
Abu-Khalaf
Maysa
M
Saif
Muhammad Wasif
MW
D000230:Adenocarcinoma / Q000150:complications* / Q000188:drug therapy; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000069347:Erlotinib Hydrochloride; D017809:Fatal Outcome; D006530:Hepatorenal Syndrome / Q000139:chemically induced*; D006801:Humans; D017093:Liver Failure / Q000139:chemically induced*; D008297:Male; D010190:Pancreatic Neoplasms / Q000150:complications* / Q000188:drug therapy; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride